Skip to main content
. 2020 Jan 14;26(2):199–218. doi: 10.3748/wjg.v26.i2.199

Figure 3.

Figure 3

Changes in the concentration of Scr after treatment in patients with renal dysfunction. A: A downtrend in the rifaximin group; B: An uptrend in the control group.